Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) are steroid-free anti-inflammatory treatments for Atopic Dermatitis. There are two: Tacrolimus ointment (Protopic, 0.03% and 0.1%) for moderate to severe eczema, and Pimecrolimus 1% cream (Elidel) for mild to moderate eczema. They block calcineurin, a protein T-cells need to switch on, so they dampen the Th2 Immune Response that drives inflammation and itch (National Eczema Society). Unlike Topical Corticosteroids (TCS), they do not thin the skin. The Axon 2021 umbrella review found TCS carried a higher risk of skin thinning than TCIs (RR 4.86, 95% CI 1.06–22.28; four RCTs, n=4,128). That makes TCIs especially useful on delicate skin where long steroid courses are a worry: face, eyelids, neck, skin folds and nappy-area outer genital skin. They do not cause Skin Atrophy or glaucoma (PCDS). They are used twice daily to treat flares, or twice a week as maintenance (Weekend Therapy).

Tacrolimus [part-of] Topical Calcineurin Inhibitors Pimecrolimus [part-of] Topical Calcineurin Inhibitors Topical Calcineurin Inhibitors [treats] Atopic Dermatitis Topical Calcineurin Inhibitors [relates] Topical Corticosteroids Topical Calcineurin Inhibitors [prevents] Skin Atrophy

Licensing ages and the toddler gap. In the UK, tacrolimus 0.03% is licensed from age 2, tacrolimus 0.1% from age 16, and pimecrolimus from 3 months (National Eczema Society; PCDS). In the US, the FDA approved tacrolimus (2000) and pimecrolimus (2001) as second-line treatments for children aged 2 and over (Tham, Lancet Child Adolesc Health 2023). So for a 1-year-old, tacrolimus is off-label everywhere, and pimecrolimus is off-label in the US but licensed in the UK. Expert groups have argued since 2015 that pimecrolimus need not be restricted to over-2s (Taieb consensus, cited by PCDS). NICE CG57 / TA82 (2004) recommends tacrolimus as a second-line option for moderate to severe eczema, and pimecrolimus for moderate eczema of the face and neck, both in children aged 2 and over whose eczema is not controlled by TCS where further TCS risks irreversible atrophy. NICE suggests stepping up to TCIs for facial (especially eyelid) eczema that needs frequent mild steroid. The PCDS says GPs experienced in eczema can start TCIs. Some UK local formularies still limit starting them to specialists.

NICE CG57 [regulates] Topical Calcineurin Inhibitors FDA [regulates] Topical Calcineurin Inhibitors MHRA [regulates] Topical Calcineurin Inhibitors

Conflict: [NICE TA82/CG57, 2004] recommends pimecrolimus only for children aged 2 and over. [National Eczema Society, 2023; PCDS, n.d.] state the UK licence for Elidel now starts at 3 months. NICE guidance predates the licence change. Unresolved — add to open_questions.

The cancer warning and later evidence. In 2006 the FDA added a boxed (“black box”) warning. It said long-term safety was not established and cited a possible risk of lymphoma and skin cancer, based mainly on case reports, organ-transplant patients on oral tacrolimus, and animal studies. Most of the later evidence is reassuring. The PEER Registry followed 7,457 US children aged 2–17 who used pimecrolimus (26,792 person-years). By 2014 it had recorded 5 cancers and no skin cancers: standardised incidence ratio 1.2 (95% CI 0.5–2.8) for all cancers and 2.9 (0.7–11.7) for lymphoma, neither significant (Margolis, JAMA Dermatol 2015). The APPLES cohort of children using tacrolimus (n=7,954, 10 years) found no lymphoma signal (Paller, JAAD 2020, cited by PCDS). The largest synthesis, Devasenapathy et al. for the AAAAI/ACAAI guideline (Lancet Child Adolesc Health 2023), pooled 110 studies and 3.4 million patients. It found any-cancer risk of 4.70 vs 4.56 per 1,000 (OR 1.03, 95% CrI 0.94–1.11; moderate certainty), with similar results in infants, children and adults. A 2026 FAERS pharmacovigilance study found no lymphoma signal for topical tacrolimus or pimecrolimus. Health Canada removed the boxed warning for pimecrolimus (2019) and tacrolimus (2021). The UK SmPCs were amended in 2022 to drop cancer from the adverse-effects sections, though it is still listed under precautions. The US boxed warning remains.

FDA [opposes] Topical Calcineurin Inhibitors PEER Registry [supports] Pimecrolimus PEER Registry [contradicts] FDA

Conflict: [FDA boxed warning, 2006; still on US labels 2026] warns of a possible lymphoma and skin-cancer risk with TCIs. [Margolis/PEER, JAMA Dermatol 2015], [Devasenapathy, Lancet Child Adolesc Health 2023] and [Arcuri, JAAD Int 2026] find no increased cancer risk, and Health Canada and the UK SmPCs have removed or downgraded the warning. Regulators disagree on the same evidence base. Unresolved — add to open_questions.

Conflict: [Lam et al., JAMA Dermatol 2021] (11 observational studies) found no overall cancer increase but elevated lymphoma risk with TCIs (RR 1.86 vs non-active comparators; 1.35 vs TCS), and the JOELLE cohort also found a lymphoma association. [Devasenapathy et al., Lancet Child Adolesc Health 2023] (110 studies) found no cancer increase, and PCDS notes that severe eczema itself is linked with lymphoma (Mansfield, JAMA Dermatol 2020), so confounding by severity is possible. Lam’s authors judge any individual absolute risk “very small”. Unresolved — add to open_questions.

Side effects and practical use. The most common side effect is burning or stinging for about 15–20 minutes after application. It is not an allergy and usually settles within the first week (National Eczema Society), but it can upset a toddler, and parents may need to know it is expected. TCIs lower the skin’s local defences. They should not go on infected skin (Impetigo, cold sores, chickenpox, warts), and the Skin Barrier Dysfunction literature links earlier trials to viral infections including Eczema Herpeticum and molluscum. They are not used under Wet Wrap Therapy, and sun protection is advised. With tacrolimus, emollients should not be applied within 2 hours (manufacturer advice). TCIs and TCS are not put on the same area at the same time, but they can be combined: TCS on the body and TCI on the face, or TCS to settle a flare then a TCI to step down. Clinical trials showed no effect on vaccine responses. Skin responds more slowly to TCIs than to TCS, which is one reason they are second-line. Tacrolimus has strong efficacy evidence (Cochrane 2015, 20 RCTs, 5,885 participants, cited by PCDS). For proactive use, Schmitt 2011 found twice-weekly tacrolimus reduced flares (RR 0.78) but probably less than potent fluticasone (RR 0.46).

Topical Calcineurin Inhibitors [relates] Eczema Herpeticum Topical Calcineurin Inhibitors [relates] Infected Eczema Topical Calcineurin Inhibitors [part-of] Weekend Therapy

Not on infected or weeping-crusted skin

TCIs damp down local immunity. Do not apply to skin with impetigo, cold sores or suspected eczema herpeticum (punched-out sores, fever): get same-day medical review.

Cost and access. Round 9 found prices: Protopic 0.03% 30 g has an NHS indicative price of £23.33 (NHS dm+d, since Nov 2016); in the US a 60 g tube of generic tacrolimus 0.03% averages about $133 cash (GoodRx), pimecrolimus 30 g about $195–212 retail, and prior authorisation is needed for about half of Medicaid enrollees (see Cost of Eczema Care). NHS cost-effectiveness of twice-weekly tacrolimus maintenance was modelled by Healy et al. (Br J Dermatol 2011), but those results were not retrieved. Cost and prescribing restrictions remain a practical barrier for parents (see open questions). The fear created by the boxed warning has been linked to lower adherence (Tham 2023), which mirrors Steroid Phobia for TCS.

Topical Calcineurin Inhibitors [relates] Steroid Phobia

What parents report (evidence: anecdotal). Parents often turn to TCIs out of Steroid Phobia or when steroids stall. Positive reports dominate (tacrolimus worked “within one or two applications”, r/ScienceBasedParenting; “luckily tacrolimus worked for us” after triamcinolone failed, r/toddlers). Barriers parents describe: licensing refusals under age 2, and the boxed warning. See Parent Experiences.

Topical Calcineurin Inhibitors [relates] Parent Experiences

Connections

• Topical Corticosteroids — steroid-sparing alternative, source: NICE CG57; Axon 2021
• Tacrolimus — 0.03%/0.1% ointment, licensed from 2/16 years, source: National Eczema Society
• Pimecrolimus — 1% cream, UK licence from 3 months, source: PCDS; National Eczema Society
• PEER Registry — 7,457 children, no significant cancer excess, source: Margolis JAMA Dermatol 2015
• FDA — 2006 boxed warning still on US labels, source: Lam 2021; Arcuri 2026
• MHRA — UK SmPCs amended 2022 to drop cancer from adverse effects, source: PCDS
• NICE CG57 — second-line from age 2 (TA82), source: NICE CG57
• Weekend Therapy — twice-weekly TCI maintenance, source: Schmitt 2011; National Eczema Society
• Wet Wrap Therapy — not for use under wet wraps, source: National Eczema Society
• Eczema Herpeticum — infection risk on TCI-treated skin, source: Elias & Wakefield (PMC4565600)
• Skin Atrophy — TCIs do not cause it, source: Axon 2021; PCDS
• Atopic Dermatitis — treats, source: Cochrane 2015 (via PCDS)
• Crisaborole — alternative steroid-free topical (US ≥3 months), source: FDA Eucrisa label
• Ruxolitinib Cream — alternative steroid-free topical (US ≥2 y), source: FDA Opzelura label
• South African Eczema Guidance — first-line on sensitive sites in SA algorithm; limited public availability, source: Kannenberg 2020
• Cost of Eczema Care — UK/US prices and prior-authorisation barrier, source: NHS dm+d; GoodRx
• Parent Experiences — parent reports (anecdotal), source: round-10 forum threads
• AAD Pediatric Guideline 2026 — strong rec incl. proactive use; under-2 off-label use supported; Health Canada removed boxed warning 2021, source: JAAD 2026